Last reviewed · How we verify

VA Greater Los Angeles Healthcare System — Portfolio Competitive Intelligence Brief

VA Greater Los Angeles Healthcare System pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Low Volume iso-osmolar non-ionic radio contrast medium Low Volume iso-osmolar non-ionic radio contrast medium marketed
Acetylcysteine Inhalation Acetylcysteine Inhalation marketed
Sodium Bicarbonate Solution Sodium Bicarbonate Solution marketed Alkalinizing agent General/Supportive Care

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hospital General "Dr. Miguel Silva" de Morelia · 1 shared drug class
  2. Jennifer Gassman, PhD · 1 shared drug class
  3. The Western Pennsylvania Hospital · 1 shared drug class
  4. University of Baghdad · 1 shared drug class
  5. VA Office of Research and Development · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for VA Greater Los Angeles Healthcare System:

Cite this brief

Drug Landscape (2026). VA Greater Los Angeles Healthcare System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/va-greater-los-angeles-healthcare-system. Accessed 2026-05-17.

Related